The upregulation of miR-23a-3p and phosphoseryl-tRNA kinase (PSTK) and the downregulation of Yes1 associated transcriptional regulator (YAP) blunt HCC sorafenib efficacy via inhibiting ferroptosis [14–16]. The gene discussed is PSTK; the disease is hepatocellular carcinoma.